Instil Bio Inc Stock News
$16.63
9.22%
yesterday
Nasdaq,
Apr 03, 10:00 pm CET
Instil Bio Inc Stock News
Neutral
GlobeNewsWire
●
about one month ago
Instil Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Clinical data for AXN-2510/IMM2510 monotherapy in relapsed/refractory NSCLC in China by ImmuneOnco, as well as additional safety data in other solid tumors, anticipated in 1H 2025
Neutral
GlobeNewsWire
●
3 months ago
ImmuneOnco announced dosing of first patient in its recently initiated Phase 1b/2 clinical trial of IMM2510/SYN-2510 in combination with chemotherapy in patients with advanced NSCLC in China
Positive
Seeking Alpha
●
4 months ago
Instil Bio is a clinical-stage biotech focusing on personalized immunotherapy. SYN-2510 targets the promising PD-L1/VEGF oncology pathway. The company recently licensed assets from ImmuneOnco Biopharmaceuticals, retaining commercialization rights outside Greater China and enhancing its global market positioning. SYN-2510 is advancing to Phase 2 trials for NSCLC and TNBC, addressing a TAM foreca...
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
